DataSheet_1_DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker.zip

DDX60, an interferon (IFN)-inducible gene, plays a promotional role in many tumors. However, its function in glioma remains unknown. In this study, bioinformatic analysis (TCGA, CGGA, Rembrandt) illustrated the upregulation and prognostic value of DDX60 in gliomas. Immunohistochemical staining of clinical samples (n = 49) validated the DDX60 expression is higher in gliomas than in normal tissue (n = 20, P < 0.0001). It also could be included in nomogram as a parameter to predict the 3- and 5-year survival risk (C-index = 0.86). The biological process of DDX60 in glioma was mainly enriched in the inflammatory and immune response by GSEA and GO analysis. DDX60 expression had a positive association with most inflammatory-related functions, such as hematopoietic cell kinase (HCK) (R = 0.31), interferon (R = 0.72), STAT1 (R = 54), and a negative correlation with IgG (R = −0.24). Furthermore, DDX60 expression tends to be positively related to multiple infiltrating immune cells, while negatively related to CD56 dim nature killer cell in glioma. Some important immune checkpoints, like CTLA-4, PD-L1, EGF, CD96, and CD226, were all positively related with DDX60 (all Pearson correlation R > 0.26). The expression and correlation between DDX60, EGF, and PD-L1 were confirmed by western blot in clinical samples (n = 14, P < 0.0001) and GBM cells. These results indicated that DDX60 might have important clinical significance in glioma and could serve as a potential immune therapeutic target.

DDX60，一种由干扰素（IFN）诱导的基因，在众多肿瘤的发生发展中扮演着促进作用。然而，其在胶质瘤中的功能尚不明确。本研究通过生物信息学分析（TCGA、CGGA、Rembrandt）揭示了DDX60在胶质瘤中的上调及其预后价值。临床样本（n = 49）的免疫组化染色证实，DDX60的表达在胶质瘤中高于正常组织（n = 20，P < 0.0001）。此外，DDX60可作为参数纳入预后图，以预测3年和5年的生存风险（C-index = 0.86）。通过GSEA和GO分析，DDX60在胶质瘤中的生物学过程主要富集于炎症和免疫反应。DDX60的表达与大多数炎症相关功能呈正相关，例如造血细胞激酶（HCK）（R = 0.31）、干扰素（R = 0.72）、STAT1（R = 54），与IgG（R = −0.24）呈负相关。此外，DDX60的表达倾向于与多种浸润性免疫细胞呈正相关，而与胶质瘤中的CD56低表达自然杀伤细胞呈负相关。一些重要的免疫检查点，如CTLA-4、PD-L1、EGF、CD96和CD226，均与DDX60呈正相关（所有Pearson相关系数R > 0.26）。通过临床样本（n = 14，P < 0.0001）和GBM细胞的Western blot实验，证实了DDX60、EGF和PD-L1之间的表达和相关性。这些结果提示，DDX60在胶质瘤中可能具有重要的临床意义，并可作为潜在的免疫治疗靶点。